CEL SCI CORP
For the period ended Sep 30, 2025. Filed Dec 29, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Dec 29, 2025
CVM$1.41+4.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Stockholders’ Equity
STATEMENT OF STOCKHOLDERS' EQUITY
| Common Stock · Additional Paid-In · Accumulated | |||||
|---|---|---|---|---|---|
| Shares | Amount | Capital | Deficit | Total | |
| BALANCE, SEPTEMBER 30, 2023 | 1,581,188 | $15,811 | $500,290,475 | $(487,091,396) | $13,214,890 |
| Exercise of pre-funded warrants | 189,335 | 1,895 | (1,895) | - | - |
| 401(k) contributions paid in common stock | 4,562 | 45 | 218,672 | - | 218,717 |
| Stock issued to nonemployees for service | 13,664 | 136 | 759,765 | - | 759,901 |
| Proceeds from the sale of common stock and pre-funded warrants | 336,000 | 3,360 | 23,571,640 | - | 23,575,000 |
| Purchase of stock by officers and directors | 1,933 | 19 | 80,601 | - | 80,620 |
| Equity based compensation - employees | - | - | 4,270,180 | - | 4,270,180 |
| Share issuance costs | - | - | (2,331,760) | - | (2,331,760) |
| Net loss | - | - | - | (26,920,465) | (26,920,465) |
| BALANCE, SEPTEMBER 30, 2024 | 2,126,682 | $21,266 | $526,857,678 | $(514,011,861) | $12,867,083 |
| 401(k) contributions paid in common stock | 41,100 | 411 | 217,906 | - | 218,317 |
| Stock issued to nonemployees for service | 52,036 | 521 | 749,807 | - | 750,328 |
| Proceeds from the sale of common stock and pre-funded warrants | 4,996,700 | 49,968 | 28,241,132 | - | 28,291,100 |
| Exercise of pre-funded warrants | 733,834 | 7,338 | (7,338) | - | - |
| Purchase of stock by officers and directors | 32,116 | 321 | 219,674 | - | 219,995 |
| Equity based compensation - employees | (100) | (1) | 1,910,998 | - | 1,910,997 |
| Shares issued for settlement of clinical development | 33,333 | 333 | 350,552 | - | 350,885 |
| Share issuance costs | - | - | (3,240,565) | - | (3,240,565) |
| Net loss | - | - | - | (25,411,055) | (25,411,055) |
| BALANCE, SEPTEMBER 30, 2025 | 8,015,701 | $80,157 | $555,299,844 | $(539,422,916) | $15,957,085 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.